News and Trends 6 Dec 2022 Startup Graegis developing therapies for radiation side-effects Graegis Pharmaceuticals, a startup developing new therapies aimed at preventing the side effects of radiotherapies, is set to complete the regulatory nonclinical package allowing entry in clinical trials. The company, founded in the last quarter of 2021, spent the first year of operations running critical experiments on the new therapies, which will target radiation side […] December 6, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
In Depth 5 Dec 2022 The biggest private biotech investments in November 2022 The companies Emalex Biosciences, Osler Diagnostics and TauRx Pharmaceuticals bagged the biggest biotech investments in November 2022. Around the world, oncology and cell therapy players attracted the biggest funding rounds. We’re approaching the December holidays and, while lower than in 2021, biotech stocks overall have stayed relatively flat in the last few months. In the […] December 5, 2022 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 5 Dec 2022 Positive antibody persistence for vaccine treating mosquito disease A single shot vaccine for mosquito-borne disease chikungunya has had positive antibody persistence data 12 months after vaccination. The primary endpoint also met with a 99% seroresponse rate. The disease is caused by the chikungunya virus (CHIKV), a Togaviridae virus, transmitted by Aedes mosquitoes. Following positive immunogenicity and safety data from a phase 3 study […] December 5, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 5 Dec 2022 Fallouh Healthcare’s device to give early diagnosis for post-surgery strangulation risk U.K.-based Fallouh Healthcare is developing a device to monitor cardiac patients after surgery, which is when a condition, called cardiac tamponade, can strike. The company says patients recovering from heart surgery can be at risk from the life-threatening condition that sees fluid build-up around the heart, strangling its ability to beat properly. Fallouh Healthcare, formed […] December 5, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 5 Dec 2022 New company Liminatus Pharma Inc to develop three cancer treatments Clinical-stage biopharma company Liminatus Pharma LLC and Iris Acquisition Corp, a publicly traded special purpose acquisition company formed for the purpose of acquiring or merging with one or more businesses, announced they have entered into a definitive business combination agreement. Upon closing of the transaction, the combined company will be renamed Liminatus Pharma, Inc.. The […] December 5, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 5 Dec 2022 Singapore researchers develop affordable cancer testing method Scientists from the National University of Singapore (NUS) have discovered a novel low-cost method of testing for cancers. Called the Heatrich-BS assay, the new test sequences clinical samples that have been heated in order to isolate cancer-specific signatures found in a patient’s blood. The new method provides a promising non-invasive alternative to tissue biopsies. It […] December 5, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 5 Dec 2022 Bactobio raises £6M to search for new antimicrobials U.K. biotech company Bactobio Ltd. has closed an oversubscribed £6 million ($7.4 million) bridge financing round. The financing was led by Bridford Group, with support from angel investors Peder Holk Nielsen (former CEO and president of Novozymes) and Hugh Grant (former chairman and CEO of Monsanto). New investors included the founders of the London-based fintech […] December 5, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 5 Dec 2022 MaxCyte and Curamys sign cell and gene therapies agreement MaxCyte, Inc. and Curamys have announced the signing of a strategic platform license. MaxCyte is a cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support cell-based research. Curamys is a South Korean biotechnology company developing cell and gene therapy using cell fusion technology […] December 5, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 5 Dec 2022 Faron Pharmaceuticals provides cancer treatment update Faron Pharmaceuticals Oy has given an update on its phase I/II BEXMAB study, investigating bexmarilimab. Bexmarilimab is Faron’s wholly owned precision immunotherapy asset, in combination with standard of care (SoC) in multiple hematological malignancies. The Finnish company said an azacytidine-refractory acute myeloid leukemia (AML) patient with partial responses as communicated on October 31, 2022, achieved […] December 5, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 5 Dec 2022 First subject dosed in inflammation phase I study Innovent Biologics, Inc. and UNION therapeutics A/S have announced that the first Chinese healthy volunteer has been successfully dosed in the phase I study of orismilast, a potential best-in-class PDE4 inhibitor in global clinical phase II stage. This study is a multiple dose escalation phase I study in healthy volunteers aiming to evaluate the pharmacokinetic […] December 5, 2022 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 5 Dec 2022 Kintor Pharma says alopecia primary endpoint met Kintor Pharmaceutical Limited has announced results of a phase II clinical trial of pyrilutamide (KX-826), a potential first-in-class topical drug, for the treatment of adult female androgeneticalopecia (AGA). The company said in the study KX-826 demonstrated clinically meaningful and statistically significant improvement in hair growth as measured by target area non-vellus hair count (TAHC). In […] December 5, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Interview 5 Dec 2022 Interview: why the recently approved fecal microbiome product is causing a rumble The news last week of the FDA approving Ferring Pharmaceuticals’ first fecal microbiome product, Rebyota, caused quite a stir in the field. The news was described as a huge step, a giant leap forward and simply fantastic. Paul Feurstadt is the director of non-inflammatory bowel disease research at the Medical Research Center of Connecticut. He also […] December 5, 2022 - 5 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email